10-Q: Inspire Medical Systems Q1 2026 Earnings: Revenue Up, Net Loss Widens

Inspire Medical Systems reported a 1.6% revenue increase for Q1 2026, but a significant net loss driven by tax impacts and operational expenses.

Summary

• Revenue for the first quarter of 2026 was $204.6 million, a 1.6% increase compared to $201.3 million in the same period of 2025.
• Gross profit increased by 3.7% to $176.9 million, with gross margin improving to 86.5% from 84.7%.
• Operating expenses rose by 3.4% to $178.0 million, primarily due to an increase in selling, general, and administrative (SG&A) costs.
• The company reported an operating loss of $1.1 million, a slight improvement from a loss of $1.5 million in the prior year.
• Net loss for the quarter was $11.3 million, a significant increase from a net profit of $3.0 million in Q1 2025.
• This net loss was heavily influenced by a substantial increase in income tax expense, reaching $13.7 million compared to $1.2 million in the prior year, largely due to stock-based compensation tax shortfalls.
• Basic and diluted loss per share was $(0.39) for the quarter.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, adverse impacts from reimbursement challenges and new government programs, and the current headwinds from GLP-1 adoption, despite modest revenue growth.

Positives

• Revenue increased by 1.6% to $204.6 million, indicating continued sales growth.
• Gross margin improved to 86.5% from 84.7%, driven by a higher sales mix of the Inspire V system.
• Operating loss slightly decreased by 24.7% to $1.1 million, showing some operational efficiency gains.
• Cash provided by operating activities was $12.8 million, a significant improvement from $6.7 million used in the prior year's period.

Negatives

• Net loss widened significantly to $11.3 million from a profit of $3.0 million in the prior year.
• Income tax expense surged to $13.7 million from $1.2 million, primarily due to stock-based compensation tax shortfalls.
• SG&A expenses increased by 5.5% to $152.2 million, impacting overall profitability.
• The company faces ongoing challenges with coding and reimbursement for its Inspire V therapy, which has adversely impacted revenue and is expected to continue doing so.
• The adoption of GLP-1 drugs for OSA is currently believed to be adversely impacting revenue in the short-term.

Risks

• Ongoing uncertainty and changes in coding and reimbursement for Inspire V therapy from CMS, MACs, and other payers are adversely impacting revenue and are expected to continue.
• The WISeR program, requiring prior authorization for Medicare cases in six pilot states, caused delays and adversely impacted revenue in Q1 2026 and is expected to continue impacting revenue through 2026.
• The increasing prevalence and adoption of GLP-1 drugs for OSA may delay or reduce demand for the Inspire system.
• Potential for product liability claims and warranty claims.
• Risks associated with international product approvals and commercializations.
• Dependency on third-party suppliers and potential supply chain disruptions.
• The company's ability to sustain or increase profitability given its history of operating losses.
• Potential for adverse outcomes in ongoing legal proceedings, including securities class actions and derivative lawsuits.

Future Outlook

The company anticipates that ongoing coding and reimbursement uncertainties, as well as the WISeR program, will continue to adversely impact revenue throughout 2026. While GLP-1s may increase the long-term eligible patient pool, they are currently believed to be adversely impacting revenue in the short-term. The company believes its existing cash and investments, along with operational cash flows, will provide sufficient liquidity for at least the next twelve months.

Management Comments

• The majority of our stock awards vest annually during the first quarter of each year, which will generally concentrate the tax impact related to the tax shortfall in the first quarter of the year.
• We are actively engaging with relevant stakeholders regarding the reimbursement uncertainty affecting Inspire V and are providing support as appropriate - with a goal of limiting and moving past the uncertainty as soon as possible.
• We believe that some of these patients (treated with GLP-1s) will see a reduction in their BMI into our indication, and that some of those patients will not have their OSA fully resolved and will require further treatment. This reinforces our belief that the overall number of patients eligible for Inspire therapy will increase in the long-term due to the availability of GLP-1s, although there can be no assurance of such benefit at this time.

Industry Context

StockSavvy.ai notes that Inspire Medical Systems is navigating a complex reimbursement landscape, a common challenge for innovative medical device companies. The emergence of GLP-1 drugs as a treatment for OSA presents both a potential long-term opportunity and a short-term competitive headwind, reflecting broader trends in obesity and metabolic disease management impacting various healthcare sectors.

Legal Proceedings

• Securities class action lawsuit filed by Indiana Public Retirement System (and previously City of Pontiac Reestablished General Employees Retirement System) alleging violations of securities laws related to the Inspire V launch.
• Stockholder derivative lawsuits (Korte and Davis) alleging breach of fiduciary duty and other claims related to the Inspire V launch.
• Civil investigative demand from the Department of Justice regarding allegations of false claims submitted to government payors.
• False Claims Act qui tam lawsuit filed by a former employee alleging improper certification for Medicare reimbursement.
• Patent infringement lawsuit filed by Inspire against Nyxoah SA, with Nyxoah filing counterclaims and petitions for inter partes review.
• Patent infringement lawsuit filed by Nyxoah against Inspire, with Inspire believing it has strong defenses.
• Patent infringement lawsuit filed by Nyxoah against Inspire and its European subsidiary in the Unified Patent Court.

Stakeholder Impact

• Shareholders: Negative impact due to increased net loss, wider operating loss, and ongoing legal risks, despite modest revenue growth.
• Customers (Hospitals and ASCs): Potential for increased administrative burden and processing time due to coding and reimbursement complexities.
• Patients: Continued access to therapy is supported, but potential delays or increased out-of-pocket costs due to reimbursement issues and the emergence of GLP-1 treatments.
• Employees: Continued investment in sales and marketing organization, but potential impact from financial performance and legal challenges.

Next Steps

• Actively engaging with stakeholders to resolve reimbursement uncertainty for Inspire V.
• Seeking a long-term solution for coding and reimbursement, including the creation of a separate CPT code.
• Continuing to provide education and support to field teams, customers, and physicians.
• Vigorously defending against ongoing legal proceedings.
• Monitoring the impact of GLP-1 drugs on the OSA market and patient diagnosis.

Key Dates

Recommendation

While revenue growth is present, the significant increase in net loss, driven by tax issues and operational expenses, coupled with ongoing reimbursement challenges and substantial legal risks, warrants a cautious approach. The potential long-term benefits from GLP-1s increasing the patient pool are offset by current adverse impacts. A 'hold' recommendation reflects the balance of modest top-line growth against significant profitability and legal concerns.

Keywords

Inspire Medical Systems, Obstructive Sleep Apnea, Medical Technology, Form 10-Q, Q1 2026 Earnings, Neurostimulation, Sleep Apnea Treatment, Healthcare Reimbursement